Amphastar Pharmaceuticals AI Stock Analysis
Want to see AMPH full AI Analyst Report?
Amphastar Pharmaceuticals (AMPH) AI Stock Analysis
Amphastar Pharmaceuticals
(NASDAQ:AMPH)
Overall score reflects solid underlying profitability and free cash flow but a cooled earnings/FCF trajectory and a more leveraged balance sheet. Technicals are supportive with the stock trading above key moving averages and positive momentum indicators. Valuation appears reasonable at ~12.3x earnings, and the latest earnings call was constructive (record revenue and buyback) though tempered by margin pressure and ongoing IMS remediation impacts.
Amphastar Pharmaceuticals (AMPH) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $1.22B
- Dividend Yield
- ―
- Average Volume (3M)
- 463.80K
- Price to Earnings (P/E)
- 12.7
- Beta (1Y)
- 0.69
- Revenue Growth
- 3.11%
- EPS Growth
- -4.26%
- Country
- US
- Employees
- 1,976
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - Specialty & Generic
Amphastar Pharmaceuticals Business Overview & Revenue Model
Company Description
Amphastar Pharmaceuticals, Inc., established in 1996 and based in Rancho Cucamonga, California, functions as a biopharmaceutical enterprise. The company is engaged in the creation, production, commercialization, and distribution of both generic and p...
How the Company Makes Money
Amphastar makes money primarily by selling pharmaceutical products to customers such as drug wholesalers, distributors, group purchasing organizations, hospitals, and pharmacies. Revenue is generated mainly from (1) net product sales of FDA-approved...
Amphastar Pharmaceuticals Earnings Call Summary
The call was broadly positive, supported by record revenue, record BAQSIMI and Primatene MIST sales, improved net income and adjusted earnings, progress on pipeline programs, and additional shareholder-return authorization. These positives were tempered by lower gross margin, persistent BAQSIMI pricing pressure, declines in epinephrine and glucagon, and ongoing IMS remediation costs, release delays, and backlog. Overall, the highlights significantly outweighed the lowlights.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
For the fourth quarter, management expects sales to increase in the high single-digit range compared to the fourth quarter of last year, incorporating a modest slowdown in IMS sales; IMS remediation expense was probably between $2 million and $3 million in the third quarter and will probably be a little bit higher than that in each of the next two or three quarters. Management is not prepared to give guidance for 2027, but expects strong growth from BAQSIMI, growth from Primatene MIST, and annualized sales of ipratropium bromide; it also expects lidocaine demand to continue into next year, API sales to continue around the same level, and strong teriparatide sales, although it may not get growth out of that. The insulin biosimilar is expected to launch next year, but there is no firm date, while AMP-018 is expected to have a limited opportunity due to the competitive nature of that environment and remains on track for the 2027 commercialization; the company’s goal is to file AMP-104 by the end of 2028.
Amphastar Pharmaceuticals Financial Statement Overview
Summary
Profitable and cash-generative (TTM gross margin ~46.8%, net margin ~13.3%, TTM FCF ~$139M), but fundamentals have cooled versus 2023–2024 with lower TTM net income (~$99M) and negative TTM FCF growth (-9.1%). Balance sheet is adequate yet more leveraged (debt ~$692M) with ROE down to ~10.1% TTM.
Income Statement
74PositiveBalance Sheet
63PositiveCash Flow
71Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 745.79M | 719.89M | 731.97M | 644.39M | 498.99M | 437.77M |
| Gross Profit | 349.09M | 356.06M | 373.86M | 351.12M | 248.86M | 199.74M |
| EBITDA | 220.70M | 212.31M | 277.31M | 240.29M | 146.16M | 110.49M |
| Net Income | 98.96M | 98.09M | 159.52M | 137.54M | 91.39M | 62.12M |
Balance Sheet | ||||||
| Total Assets | 1.71B | 1.63B | 1.58B | 1.51B | 741.99M | 671.53M |
| Cash, Cash Equivalents and Short-Term Investments | 230.63M | 282.81M | 221.65M | 256.81M | 175.76M | 136.67M |
| Total Debt | 691.69M | 656.00M | 650.55M | 623.64M | 102.58M | 104.66M |
| Total Liabilities | 897.17M | 840.49M | 845.17M | 873.49M | 213.33M | 226.01M |
| Stockholders Equity | 814.55M | 788.80M | 732.30M | 639.42M | 528.66M | 445.52M |
Cash Flow | ||||||
| Free Cash Flow | 139.01M | 121.23M | 172.34M | 145.34M | 65.15M | 70.54M |
| Operating Cash Flow | 175.33M | 156.12M | 213.39M | 183.50M | 89.18M | 97.99M |
| Investing Cash Flow | -96.40M | -70.33M | -124.93M | -649.12M | -32.78M | -28.67M |
| Financing Cash Flow | -90.41M | -67.42M | -80.95M | 454.09M | -26.44M | -37.02M |
Amphastar Pharmaceuticals Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AMPH, the sentiment is Positive. The current price of 28.60 is above the 20-day moving average (MA) of 26.96, above the 50-day MA of 25.74, and above the 200-day MA of 22.33, indicating a bullish trend. The MACD of 0.92 indicates Negative momentum. The RSI at 63.15 is Neutral, neither overbought nor oversold. The STOCH value of 57.65 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AMPH.
Amphastar Pharmaceuticals Risk Analysis
Amphastar Pharmaceuticals disclosed 86 risk factors in its most recent earnings report. Amphastar Pharmaceuticals reported the most risks in the "Legal & Regulatory" category.
Latest Risks Added
3 New RisksAmphastar Pharmaceuticals Peers Comparison
Overall Rating
- AMPH72Outperform
ANIP72Outperform
PCRX66Neutral
TEVA65Neutral
AMRX58Neutral
VTRS58Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| AMPH | 72Outperform | $1.24B | 12.71 | 12.59% | ― | 3.11% | -4.26% |
| ANIP | 72Outperform | $1.64B | 13.72 | 20.00% | ― | 25.94% | 203.25% |
| PCRX | 66Neutral | $1.46B | 38.29 | 5.53% | ― | 3.70% | 101.62% |
| TEVA | 65Neutral | $49.58B | 101.81 | 9.18% | ― | 2.99% | -28.63% |
| AMRX | 58Neutral | $7.45B | 50.49 | 131.71% | ― | 8.88% | 2272.07% |
| VTRS | 58Neutral | $23.90B | -39.73 | -4.24% | 2.28% | 4.80% | 82.97% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| AMPH | Amphastar Pharmaceuticals Inc | 28.60 | 2.23 | 8.46% | |
| VTRS | Viatris, Inc. | 21.06 | 10.52 | 99.89% | |
| PCRX | Pacira | 36.46 | 12.84 | 54.36% | |
| TEVA | Teva Pharmaceutical Industries Limited | 43.24 | 17.24 | 66.31% | |
| ANIP | Ani Pharmaceuticals | 71.09 | -13.46 | -15.92% | |
| AMRX | Amneal Pharma | 21.71 | 10.19 | 88.45% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 06, 2026